Serum ceramides could predict durable diabetes remission following gastric bypass surgery
Eric Hajduch1, Hervé Le Stunff2
1Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, 75006 Paris, France.
Med (New York, N.Y.)
|July 9, 2022
Abstract:
Morbid obesity is a major risk factor for the development of type 2 diabetes (T2D). One strategy to both lose weight and counteract T2D is bariatric surgery (RYGB). In a study published in this issue of Med, Poss et al. revealed that circulating ceramides could predict the durability of T2D remission independently of weight loss following RYGB.
